↓ Skip to main content

Dove Medical Press

Article Metrics

Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease

Overview of attention for article published in International Journal of Nephrology and Renovascular Disease, April 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
28 Mendeley
Title
Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
Published in
International Journal of Nephrology and Renovascular Disease, April 2012
DOI 10.2147/ijnrd.s23447
Pubmed ID
Authors

Naro Ohashi , Sakao, Yasuda, Kato, Fujigaki

Abstract

Chronic kidney disease (CKD) is a risk factor for end-stage renal failure and cardiovascular events. In patients with CKD, anemia is often caused by decreased erythropoietin production relative to hemoglobin levels. As correction of anemia is associated with improved cardiac and renal function and quality of life, erythropoiesis-stimulating agents (ESAs) are standard therapy for anemia in CKD patients. However, traditional ESAs such as epoetin or darbepoetin have short half-lives and require frequent administration, dose changes, and close monitoring of hemoglobin concentration to maintain target hemoglobin levels. Methoxy polyethylene glycol-epoetin beta (MPG-EPO) is the only ESA that is generated by chemical modification of glycosylated erythropoietin through the integration of one specific, long, linear chain of polyethylene glycol. This ESA induces continuous erythropoietin receptor activation and has a long half-life (approximately 130 hours). Subcutaneous or intravenous administration of MPG-EPO once every 2 weeks or monthly achieved a high hemoglobin response rate in patients with anemia associated with CKD, regardless of whether the patient was undergoing dialysis. According to data from an observational time and motion study, MPG-EPO maintains hemoglobin levels when the same dose is administered, however infrequently. This suggests that compared with the use of traditional ESAs, administration of MPG-EPO reduces the overall time and cost associated with the management of anemia in CKD patients undergoing dialysis. MPG-EPO is generally well tolerated and most adverse events are of mild to moderate severity. The most commonly reported adverse effects are hypertension, nasopharyngitis, and diarrhea. Subcutaneous injection of MPG-EPO is significantly less painful than subcutaneous injection of darbepoetin. In conclusion, MPG-EPO is as effective and safe as traditional ESAs in managing renal anemia, irrespective of whether the patient is undergoing dialysis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 5 18%
Student > Bachelor 5 18%
Student > Ph. D. Student 5 18%
Researcher 4 14%
Other 2 7%
Other 5 18%
Unknown 2 7%
Readers by discipline Count As %
Medicine and Dentistry 13 46%
Pharmacology, Toxicology and Pharmaceutical Science 4 14%
Nursing and Health Professions 2 7%
Unspecified 2 7%
Agricultural and Biological Sciences 2 7%
Other 3 11%
Unknown 2 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2012.
All research outputs
#3,533,867
of 4,506,935 outputs
Outputs from International Journal of Nephrology and Renovascular Disease
#49
of 71 outputs
Outputs of similar age
#58,563
of 75,175 outputs
Outputs of similar age from International Journal of Nephrology and Renovascular Disease
#4
of 6 outputs
Altmetric has tracked 4,506,935 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 71 research outputs from this source. They receive a mean Attention Score of 1.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,175 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.